Jupiter Neurosciences licenses MDMA drug in deal worth up to $100M
What's the deal? Jupiter NeurosciencesDealroom has a profile for this one. Try Dealroom → (Nasdaq: JUNS) has signed a definitive licensing agreement with PharmAla BiotechDealroom has a profile for this one. Try Dealroom → for perpetual exclusive US rights to ALA-002, a patented MDMA formulation. The deal is valued at up to $100 million including milestones.
What's the endgame? The agreement turns Jupiter into a dual clinical-stage central nervous system (CNS) company. ALA-002 joins its existing Phase II Parkinson's disease program and JOTROL portfolio.
Who's behind it? Jupiter is led by co-founder, chief executive officer and chairman Christer Rosén, who previously founded EffRx PharmaceuticalsDealroom has a profile for this one. Try Dealroom → — acquired by Abiogen in 2023 — and secured FDA and EU approvals for the osteoporosis drug Binosto. President and chief operating officer Alison Silva co-founded Synlogic and previously held drug-development roles at SLA Pharma, Marina Biotech, and Pfizer.
What is ALA-002? It is a patented, non-racemic MDXX molecule for which Jupiter now owns the exclusive US license. Rosén and Silva discussed its primary indication, addressable market size, and potential revenue relative to the acquisition cost in a fireside chat hosted by IPO Edge.
Why now? The deal lands as US regulators and the federal government reassess their position on the psychedelics field, shaping how clinical trials will run in the coming years.
The signal: Jupiter's move reflects growing interest in psychedelic therapies as licensing targets, as small-cap biotechs use M&A to broaden CNS pipelines without building programs from scratch.
